Introduction
Invasive fungal infections (IFIs), especially invasive mold infections (IMIs), have become major causes of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT) over the past two decades. [1] [2] [3] [4] Specifically, late invasive aspergillosis (IA) emerged as a particular concern in patients receiving continual immunosuppression for chronic GVHD and is a major cause of morbidity and mortality. [1] [2] [3] [4] During this same period, physicians began using several new drugs for antifungal prophylaxis; a practice that is now supported by results of prospective randomized trials performed in the HSCT population. 5 Consequently, researchers from both sides of the Atlantic have introduced a flurry of guidelines, [6] [7] [8] [9] relying heavily on the quality of evidence of these industrysponsored prospective trials. However, is this the final word in the approach to antifungal prophylaxis with HSCT? How applicable are these selective trials to 'real-life' and institutionally focused decisions governing prophylactic strategies? More importantly, the investigators in these trials assumed that the IFI risk remains rather constant throughout the natural history of hematopoietic SCT. Yet, the risk for IFI and spectrum of possible pathogen exposure is heterogeneous over the time course of the transplant. 10, 11 Because change in the profile of contemporary transplant recipients (for example, fewer patients with CML, transplantation in older patients with comorbidities) and transplantation procedures (for example, more nonmyeloablative HSCTs, peripheral and cord blood SCTs, increasing stem cell doses, CD34 stem cell selection/T-cell depletion) have evolved constantly, 10 antifungal prophylaxis has been a 'moving target' where consensus is difficult. Some examples are worth mentioning. For example, no studies have extensively looked into the impact of biologic stimulation of mucosal recovery (for example, using recombinant human keratinocyte growth factor) 12 or of growth factors (for example, G-CSF) 13 on the risk of IFIs (mainly candidiasis) in the preengraftment period, even without antifungal prophylaxis. Similarly, few studies have systematically evaluated the impact of glucose control or treatment of iron overload 14 on the postengraftment period in patients in HSCT recipients with steroid-dependent GVHD. In the end, IFI risk in these patients is (1) the synthesis of many competing factors that increase or decrease risk and (2) not static. Suboptimal performance of diagnostic tests for fungal infections 15 and the demise of the autopsy as 'gold standard' of diagnosis 16 have made these questions even more difficult to answer. Thus, determining optimal approach to antifungal prophylaxis is a timely question in view of a constantly increasing number of reports on the use of new tools for IFI risk stratification (genetic, metabolic) and the ever-increasing emphasis on cost of antifungals and selection for fungal resistance. Several points in this increasingly complex issue are worth highlighting.
Fluconazole remains the drug to beat
Although the value of fluconazole in prevention of candidiasis in hematopoietic SCT recipients is well established, 17, 18 no completely safe, practical, effective regimen for preventing IA or other IMIs exists. 19 In fact, fluconazole has been the only drug exhibiting a survival benefit in these patients. 19, 20 Also, a recent randomized multi-institution study failed to show that prophylaxis with the mold-active agent voriconazole was more beneficial than prophylaxis with fluconazole and surveillance (screening for Aspergillus galactomannan twice a week), at least in HSCT recipients with a moderate risk for IFIs. 21 Therefore, whether use of universal broad-spectrum antifungal prophylaxis (for example, with posaconazole) or continuing prophylaxis with fluconazole and intense monitoring using computed tomography and/or screening with serology markers (for example, Aspergillus galactomannan, with or without 1-3-bD-glucan) remains controversial. Importantly, many transplant centers may find the latter strategy difficult to implement because of logistical problems in coordinating patient assessment among the clinical microbiology laboratory, radiology, infectious diseases and hematology personnel. Finally, researchers have yet to definitively prove that broad-spectrum antifungal prophylaxis reduces mortality rates for infections with fluconazoleresistant fungi, including molds. 21, 22 At the end of the day, no matter what antifungal is used as prophylaxis, a variety of breakthrough IFIs, albeit uncommon, will always occur in high-risk SCT recipients, even infections resistant to prophylactic agents with broad spectra of activity. [23] [24] [25] [26] [27] [28] [29] The reasons for the occurrence of such breakthrough IFIs are multiple and frequently interrelated (Figure 1 ), including refractory GVHD, relapse of leukemia after HSCT, persistent immunosuppresion, suboptimal blood concentrations of voriconazole or posaconazole 30, 31 and even geoclimatic exposures to fungi.
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No mold-active prophylactic regimen is perfect Currently available mold-active antifungals include triazoles (itraconazole, voriconazole and posaconazole), echinocandins (caspofungin, micafungin and anidulafungin) and amphotericin B (AMB) formulations (AMB-d, liposomal AMB (Ambisome, Gilead Sciences, San Dimas, CA, USA), AMB lipid complex (Abelcet, Sigma-Tau PharmaSource, Indianapolis, IN, USA)). All of these agents have distinct toxicity and pharmacologic profiles. 33 The most popular prophylactic approach for IMIs, triazole-based prophylaxis, is feasible and effective, especially using posaconazole or voriconazole. Yet, how many of these trials examining antifungal prophylaxis reflect real-life challenges associated with antifungal prophylaxis? For example, baseline liver dysfunction is common following HSCT, 34 and thus, a large subset of transplant recipients is excluded from enrollment in industry-sponsored trials. The pharmacokinetic limitations of the new triazoles, the hepatotoxicity with voriconazole are common issues. 30, 31 Whether monitoring of voriconazole serum levels prevents such toxic effects is unclear. 31 The clinical differentiation of such toxicity from hepatotoxicity caused by other sources (for example, liver GVHD, reactivation of intercurrent viral pathogens) in HSCT recipients is difficult, 34 but clinicians are quick to blame use of antifungals as the leading cause of this toxicity.
Is therapeutic drug monitoring required for effective mold-active prophylaxis? Therapeutic drug monitoring use when the new triazoles are administered prophylactically is probably a good idea in view of the tremendous interpatient and intrapatient variability in voriconazole metabolism (partly driven by pharmacogenetic differences in its metabolism) and poor absorption of posaconazole in patients with GVHD of the gut, mucositis, diarrhea, proton-pump inhibitor use or poor oral intake. 30, 31, [34] [35] [36] [37] However, the available, good-quality, prospectively obtained data in the prophylactic setting are insufficient to justify the routine use of therapeutic drug monitoring. In addition, logistics, cost and incorporation of therapeutic drug monitoring have yet to be worked out in modern prophylactic algorithms. 31 Which triazole is best for antifungal prophylaxis? The available data preclude evaluation of the superiority of voriconazole over posaconazole in broad-spectrum prophylaxis in HSCT recipients, as no studies have directly compared these agents. These studies had different designs, study populations and, importantly, timing of prophylaxis initiation (voriconazole at the time of HSCT and posaconazole at the onset of GVHD). 21, 22 Therefore, whether the number of patients needed to treat or prevent an IFI 38 favors posaconazole over voriconazole during the preengraftment period or in the setting of GVHD is unknown. Another interesting unexplored area is the sequential exposure to different triazoles and its impact on resistance, performance of diagnostic tests and preemptive and targeted antifungal therapy. In real life, this may dictate 'downstream' antifungal approaches used. For example, because most HSCT recipients have leukemia, these patients are already frequently using broad-spectrum antifungals, such as prophylaxis (for example, posaconazole, voriconazole), during introduction or consolidation; thus, the transplant physician may have difficulty in downgrading the prophylactic agent (for example, from voriconazole to fluconazole), even if the patient undergoes 'low-risk' HSCT (for example, that with cells from a matched sibling). Finally, which triazole that is safest in antifungal prophylaxis over the long term is unclear.
Is there a role for parenteral prophylaxis in SCT?
Despite their expense and need for i.v. administration, echinocandins and lipid formulations of AMB probably still have a role in prophylaxis, including in patients who cannot tolerate oral medications, cannot receive azoles because of drug interactions or liver dysfunction or have medical insurance that covers i.v. but not expensive oral medications. The 'depot' pharmacokinetic characteristics of liposomal AMB formulations may allow biweekly or even weekly administration. However, there is a paucity of robust, well-powered studies to address this question. [39] [40] [41] Studies of echinocandins in antifungal prophylaxis in HSCT recipients are often limited to low-risk patients or single-institution retrospective studies. 42, 43 Preclinical data suggest that administration of echinocandins every other day is promising 44 and makes them more practical than daily administration in the outpatient setting.
Prophylaxis with systemic antifungals is likely more effective than that with topical (inhaled or non-absorbable) antifungals Whereas prophylaxis with non-absorbable oral or inhaled antifungals may have a role in some settings (for example, lung transplantation), these approaches may be less feasible to systemic therapy because many pathogens, such as Candida species, translocate from the gut or as in the case of molds, involve sinopulmonary (especially distal) airways and tend to disseminate. A recent randomized study of inhaled liposomal AMB vs a placebo that focused primarily on non-SCT patients with leukemia receiving concomitant prophylaxis with fluconazole suggested that inhaled lipid formulations of AMB were well tolerated and potentially efficacious. 45 However, concentration of these inhaled agents in subpleural compartments, the theoretical risk of resistance because of a gradient in the concentration antifungals from proximal to distal airways and the lack of solid experience in the hematopoietic setting raise concerns about the degree of protection provided by this approach. Furthermore, local application of antifungals does not adequately protect these sites against dissemination. As a pioneering hematologist (Emil Freireich) at our institution once said 'There is no real antifungal prophylaxis, but only early treatment of subclinical disease.'
The promise of and confusion caused by the genetic stratification of risk of IFIs Researchers derived many of the schemes used to stratify the risk of IFIs, especially IA, from older cohorts of HSCT recipients (for example, when TBI, myeloablative HSCT) before the era of mold-active prophylaxis with drugs, such as voriconazole or posaconazole. Recent studies implicating metabolic factors 46, 47 and genetic association studies [48] [49] [50] [51] [52] [53] [54] [55] [56] pointed out new subgroups of potential IFI risk factors. Specifically, single-nucleotide polymorphisms in Toll-like receptor genes in hematopoietic stem cell donors, single-nucleotide polymorphisms in the plasminogen gene in HSCT recipients, IL-1 gene polymorphisms and haplotypes, the chemotactic cytokine CXC10 polymorphisms, dectin-1 deficiency, baseline mannose-binding lectin levels before transplantation and iron overload assessed using iron staining in BM or measurement of serum ferritin levels were associated with increased risk of IA in HSCT recipients. [48] [49] [50] [51] [52] [53] [54] [55] [56] Table 1 depicts summary of published potential genetic risk factors for IFI's in SCT recipients. However, the issues of selective reporting and whether use of these markers enhances the clinical facts and routine laboratory predictors remain unresolved. Specifically, the hierarchical importance of use of these new markers alone or in combination with well-established risk factors for IFI is not understood. Additionally, the predictive value of genetic risk factors diminishes when antifungal prophylaxis is administered. Which of these new markers are independent predictors of IFIs per se but not for conditions associated with increased IFI risk (for example, leukemia relapse, hyper acute GVHD or GVHD refractoriness, CMV reactivation risk, increased azole antifungal metabolism) also remains to be seen. For example, associations of toll-like receptor (TLR) polymorphisms with risk for GVHD have been reported. 57, 58 In fact, the interplay between risk of fungal colonization or fungal disease and GVHD risk might be complicated. van der Velden et al. recently reported that patient-donor pairs having the wildtype dectin-1 allele who were colonized with Candida had increased incidence of acute GVHD compared with the non-colonized patients. 59 Interestingly, colonized patients bearing the dectin-1Y238X polymorphism, a loss-of-function mutation associated with increased risk of Candida colonization (Table 1) 52 had less acute GVHD, despite increased rates of Candida colonization, implying the complicated role of C-type lectins receptor-mediated Th17 responses to incidence of GVhD and Candida colonization. 59 More studies, ideally in ethnically diverse patient groups, would further refine the existing traditional crude, host-based risk-stratification schemes for IFIs. However, this is an area not yet 'mature' enough for clinical implementation, and whether these new tools would accomplish something beyond what is currently available and ultimately changes IFI risk-stratification practice remains to be determined.
What are some reasonable choices for antifungal prophylaxis in hematopoietic SCT recipients? Clearly, the factors that influence the selection of antifungals for prophylaxis are complex and difficult to summarize. In my opinion, local epidemiology, hospitalspecific logistics and risk stratification based on the profiles of different subpopulations of patients receiving transplants in the center in question as well as costs should dictate policies. No antifungal prophylaxis strategy should be a substitute for careful infection control and education of patients on how to avoid exposure to high-fungal inocula. 60 The latter is an important unexplored direction in view of the increased mobility and outpatient nature of most HSCTs, 61 the recipients of which continue to have varying chronic forms of immunosuppression (for example, chronic use of corticosteroids for GVHD). With these caveats in mind, the following are some general recommendations.
Candidates for fluconazole-based prophylaxis Autologous hematopoietic SCT recipients. Administration of fluconazole (200-400 mg/day) starting on day 0 (oral or i.v., based on the presence of mucositis) and continuing until resolution of neutropenia and mucositis.
Matched sibling allogeneic hematopoietic SCT recipients with no prior history of IMIs. Administration of fluconazole (400 mg/day; 6 mg/kg/day) starting on day 0 (oral or i.v., based on the presence of mucositis) and continuing for 75 days in both myeloablative and non-myeloablative allograft recipients until neutrophil recovery (41000 for 3-4 consecutive days; restart for in patients with secondary graft failure.
Mold-active prophylaxis
Again, the type and duration of antifungal prophylaxis should depend on the relative risks for invasive candidiasis, IA and other IMIs, such as mucormycosis. For example, at my institution, more than 40% of IMIs are caused by nonAspergillus hyalohyphomycetes and Zygomycetes (a fungus resistant to voriconazole). 33 Non-fumigatus Aspergillus species cause two-thirds of these IMIs, whereas Aspergillus terreus (an AMB-tolerant species) causes one-third of them. 23 Therefore, use of broad-spectrum antifungals seems the preferred prophylactic strategy for IMIs here. Table 2 depicts the risk factors for IA and mucormycosis in HSCT recipients and Figure 2 , a suggested approach. Table 2 Hematopoietic stem cell transplant recipients at highest risk for IA and other IMIs 
Iron overload
Baseline serum ferritin 41000 ng/mL 3-4+ iron in BM Iron overload by liver MRI Diabetes mellitus or chronic hyperglycemia due to corticosteroids Pre-exposure to Aspergillus-active antifungals (e.g. VRC, echinocandins) Abbreviations: ATG ¼ antithymocyte globulin; IA ¼ invasive aspergillosis; IMI ¼ invasive mold infection; MRI ¼ magnetic resonance imaging; RSV ¼ syncytial respiratory virus; VRC ¼ voriconazole. Table 3 lists questions about antifungal prophylaxis in HSCT recipients that remain unanswered. At my institution, we continue administering mold-active prophylaxis to corticosteroid-treated patients who have GVHD after undergoing SCT up to 1 month after weaning them off corticosteroids.
Should hematopoietic SCT recipients undergoing mold-active prophylaxis be subjected to screening for Aspergillus galactomannan? The complexities and challenges of using non-culture based surrogate markers (for example, Aspergillus gallactomannan, 1-3-bÀD-glucan, PCR) for screening is beyond the Table 2 ) might be reasonable, although it is unclear whether it is cost effective. All positive results require verification by retesting a new aliquot of the same specimen or demonstration of reproducibility in a new specimen.
Conclusion
We are currently in the era of personalized medicine, and the field of antifungal prophylaxis is no exception. Introduction and use of novel molecular markers of IFI risk, availability of diagnostic tools (for example, in-house Aspergillus galactomannan testing, therapeutic drug monitoring, easy accessibility to computed tomography) and IFI risk stratification based on time-honored host characteristics (for example, severity and persistence of underlying immunosuppressing condition, antifungal selection pressure, metabolic impairment, quantitative innate and adaptive immune defects, advanced age, poor performance status) are expected to fundamentally alter our approach to this risk stratification in HSCT recipients and, thus, antifungal selection over the upcoming decade. Regular reviews of policies, surveillance for resistant breakthrough infections, appropriate antifungal stewardship programs simulating similar endeavors in antimicrobial stewardship programs 66 (for example, development of a formalized strategy to ensure that anti-infectives, including antifungals are utilized optimally) and vigorous cost-effectiveness analyses 67 should complement this individualized approach to antifungal prophylaxis in HSCT recipients. The current literature and the ever evolving epidemiology allow some simple take home messages for the clinician (Table 4 ). The next decade is expected to be an exciting era, perhaps leading to the 'holy grail' of prophylaxis: refinement of risks that leads to appropriate antifungal use and screening.
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